COLLINS HELEN LOUISE (CHIEF MEDICAL OFFICER) sold 16.7% of their position (5K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $199.0K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 5/20/2026ACC: 0001701247-26-000007
Officer· CHIEF MEDICAL OFFICER
Since Feb 2026
-5K
Net shares
Net seller
$199.0K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
5K acquired · 10K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+5K
Price / share
$2.48
Trade value
$12.40K
% of position
20.0%
5/18/2026
25K→30K
Common Stock
Direct
Shares
−3.48K
Price / share
$39.53
Trade value
$137.38K
% of position
11.6%
5/18/2026
30K→26.52K
Common Stock
Direct
Shares
−1.30K
Price / share
$40.25
Trade value
$52.40K
% of position
4.9%
5/18/2026
26.52K→25.22K
Common Stock
Direct
Shares
−223.00
Price / share
$41.21
Trade value
$9.19K
% of position
0.9%
5/18/2026
25.22K→25K
Total
Net shares
+0.00
Net value
-$186.57K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/18/2026 | M · Option Exercise | +5K | $2.48 | $12.40K | 20.0% | 25K | 30K |
| Common Stock Direct | 5/18/2026 | S · Sale | −3.48K | $39.53 | $137.38K | 11.6% | 30K | 26.52K |
| Common Stock Direct | 5/18/2026 | S · Sale | −1.30K | $40.25 | $52.40K | 4.9% | 26.52K | 25.22K |
| Common Stock Direct | 5/18/2026 | S · Sale | −223.00 | $41.21 | $9.19K | 0.9% | 25.22K | 25K |
| Total | +0.00 | -$186.57K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
5K shares
Shares
−5K
Strike price
2.48
Held after
126.27K
Exercisable
—
5/18/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock5K shares | 5/18/2026 | M · Option Exercise | −5K | 2.48 | — | 126.27K |